title: Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
abstract: In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found significant differences in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.
authors.affiliation: Department of Immunology and Microbiology, 1st Medical Faculty, Charles University, General Teaching Hospital in Prague, Karlovo náměstí 32, 121 11 Prague 2, Czech Republic. zuzana.humlova@seznam.cz
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Humlová
authors.forename: Hana
authors.initials: H
authors.lastname: Klamová
authors.forename: Ivana
authors.initials: I
authors.lastname: Janatková
authors.forename: Karin
authors.initials: K
authors.lastname: Malíčková
authors.forename: Petra
authors.initials: P
authors.lastname: Králíková
authors.forename: Ivan
authors.initials: I
authors.lastname: Sterzl
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Roth
authors.forename: Eva
authors.initials: E
authors.lastname: Hamšíková
authors.forename: Vladimír
authors.initials: V
authors.lastname: Vonka
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D002097:C-Reactive Protein / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis; D000069439:Dasatinib; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D000068877:Imatinib Mesylate; D007113:Immunity, Innate; D007136:Immunoglobulins / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000628:therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000378:metabolism; D013844:Thiazoles / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007136:Immunoglobulins; D007155:Immunologic Factors; D016898:Interferon-alpha; D015850:Interleukin-6; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D003165:Complement System Proteins; D002097:C-Reactive Protein; D000069439:Dasatinib; D006918:Hydroxyurea